

ALLIGATOR BIOSCIENCE ANNOUNCES THE PROMOTION OF LAURA VON SCHANTZ TO CHIEF TECHNOLOGY OFFICER

Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the promotion of Laura von Schantz to Chief Technology Officer, and her joining the executive management team. In this role, Laura will oversee all technical aspects in the development of Alligator's best-in-class preclinical and clinical pipeline, including lead assets mitazalimab, a CD40 agonist currently in Phase 2 clinical development, and ATOR-1017, a Phase 2-ready 4-1BB agonist.

Laura joined Alligator in 2014 and was most recently Vice President, Discovery, a position she held since January 2021 and in which she played a key role in securing Alligator's research agreements most recently with Orion Corporation, as well as restructuring and invigorating the company's Discovery function. Prior to that, Laura was Director, Antibody Engineering where she was responsible for Alligator's technology platform.

During her time with the company, Laura has also been instrumental in the invention of Alligator's RUBY™ bispecific format and has led the establishment of antibody engineering that can generate functional and developable candidate drugs at a competitive pace. She holds a PhD in Immuno-technology and an MSc in Biotechnology, both from Lund University.

*"It's with great pleasure that we welcome Laura to her new role as Alligator's Chief Technology Officer and part of our executive management team," said **Søren Bregenholt, CEO of Alligator Bioscience.** "Laura is the natural choice for the role to drive continued development of Alligator's technology platforms, while at the same time ensure we deliver on our internal and partnered discovery programs. She has a deep knowledge of the company and our past scientific achievements and future goals. Laura steps into the role at a pivotal time for Alligator as we prepare to advance and expand our preclinical and clinical pipeline and we will benefit greatly from her knowledge and expertise."*

PRESS RELEASE

13 February 2023 08:30:00 CET



*"The use of cutting-edge technology is a core part of Alligator's innovative scientific approach, and I am very excited to be assuming this vital role," said **Laura von Schantz, CTO of Alligator Bioscience.** "I am extremely proud of the recent advancements of our clinical and preclinical programs, and I look forward to continuing my contribution to the company's goal of developing meaningful therapies for patients with hard-to-treat cancers."*

The information was submitted for publication, through the agency of the contact persons set out below, at 8:30 a.m. CET on February 13, 2023.

For further information, please contact:

Søren Bregenholt, CEO

E-mail: soren.bregenholt@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: gvanrenterghem@lifesciadvisors.com

Phone: +41 (0) 76 735 01 31

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

PRESS RELEASE

13 February 2023 08:30:00 CET



Attachments

Alligator Bioscience Announces the Promotion of Laura von Schantz to Chief Technology Officer